Sarepta Therapeutics, Inc. (SRPT) Technical Analysis & Indicators

Sarepta Therapeutics, Inc. (SRPT) — Price $18.99 (closing price, November 4, 2026) — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Technical analysis of Sarepta Therapeutics, Inc. (SRPT): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases.

Price Performance

1 month+11.09%
3 months+14.60%
Year-to-date-10.64%
1 year+3.00%
3 years-75.99%
5 years-78.38%
10 years-50.51%

52-Week Range

52-week High$24.68
52-week Low$14.68
Avg Volume (90d)3.2M

Technical Indicators

SMA 50$19.25
SMA 200$18.74
Beta0.28
30-day Volatility (annualised)55.7%
Price vs SMA 50-0.1%
Price vs SMA 200+2.6%

Monthly Close (12 months)

MonthCloseChange
2025-12$21.52
2026-01$20.34-5.5%
2026-02$16.76-17.6%
2026-03$21.76+29.8%
2026-04$20.88-4.0%
2026-05$17.87-14.4%
2026-06$17.97+0.6%
2026-07$14.86-17.3%
2026-08$21.03+41.5%
2026-09$18.22-13.4%
2026-10$19.23+5.5%

Upcoming Earnings

DateEPS Est.Revenue Est.
2026-11-05$0.07$352M
2026-08-05$0.22$366M
2026-05-06$0.98$474M
2026-02-25$-1.03$370M
2025-11-03$-0.73$336M
2025-08-06$0.83$531M
2025-05-06$-0.87$687M

Price

Price$18.99 (closing price, November 4, 2026)
Market Cap$2.0B
ExchangeNASDAQ
CountryUS

Valuation Ratios

Price / Book1.30
Dividend Yield0.00%

Financial Health

Debt / Equity0.68
Current Ratio4.42
Piotroski F-Score3
Altman Z-Score-0.90

Related companies: ALNY · IONS · PTCT · DYN

Explore sector: Healthcare · Biotechnology

More sections of SRPT: Overview · Financials · Valuation · Estimates · Ownership

Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks